Shares in TransEnterix (NYSE:TRXC) have dipped today despite the robotic surgical maker announcing yesterday that it landed the 1st sale of the system in Germany.

The Research Triangle, N.C.-based company sold the 1st Senhance surgical system in the country to St. Marien-Krankenhaus Siegen. The hospital said it will use the device to establish a robotic surgical program that will initially focus on general and gynecologic surgery.

“We chose the Senhance to bring robotic surgical assistance to the treatment of our patients. The combination of robotic precision, advanced visualization, and haptic technology are important to further offering the best minimally invasive surgery to our patients and was particularly compelling to our surgical leadership under the supervision of Dr. Dietmar Stephan. The Senhance system also allows our hospital to offer the latest technology at a reasonable cost,” St. Marien medical director Dr. Frank Willeke said in a press release.

Shares were up in mid day trading, but dipped down 1.5% to close at $1.31.

“St. Marien Hospital in Siegen chose the Senhance because of our unique combination of advanced technology and responsible economics. We have been focused on growing our capabilities to sell to and support hospitals in Germany, a critical market for our company, and are pleased to partner with one of Germany’s leading centers for minimally invasive surgery,” prez & CEO Todd Pope said in a prepared statement.

Earlier this month, TransEnterix touted the 1st clinical use of its Senhance robot-assisted surgery platform in France

The 1st French case, performed by Dr. Celine Chauleur of CHU Saint-Ètienne, was a hysterectomy to treat endometrial cancer with pelvic lymphadenectomy Feb. 7. The patient was discharged less than 24 hours after surgery, Morrisville, N.C.-based TransEnterix said.